Finapark
Cheaper & Alternative Brands
Same generic (Safinamide Mesylate), same form (Tablet)
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
Finapark is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. Finapark has not been shown to be effective as monotherapy for the treatment of Parkinson's disease.
Dosage & Administration
For Usual Initial Dosage
: The recommended starting dosage of Safinamide tablet is 50 mg orally once daily (at the same time of day). If a dose is missed, the next dose should be taken at the same time the next day.
For Maintenance dosage
: After 2 weeks, the dose may be increased to 100 mg once daily, based on individual need and tolerability. Safinamide 100 mg should be tapered by decreasing the dose to 50 mg for one week before stopping.
Use in Children
: Safety & effectiveness of Safinamide in infants & children have not been established.
Geriatric Use
: No overall differences in safety or effectiveness were observed in these patients and younger patients.
Hepatic Impairment
: Safinamide plasma concentrations are increased in patients with hepatic impairment.
Contraindications
Safinamide is contraindicated in patients with:
Concomitant use of the following drugs:
Other monoamine oxidase inhibitors or other drugs that are potent inhibitors of monoamine oxidase (e.g., linezolid)
Opioid drugs (e.g., tramadol, meperidine and related derivatives); selective norepinephrine reuptake inhibitors; tri-or tetra-cyclic or triazolopyridine antidepressants; cyclobenzaprine; methylphenidate, amphetamine, and their derivatives; St. John’s wort
Dextromethorphan
A history of a hypersensitivity to safinamide
Severe hepatic impairment (Child-Pugh C: 10-15)
Side Effects & Adverse Reactions
Most common adverse reactions of Finapark’s are dyskinesia, fall, nausea, and insomnia.
Warnings & Precautions
May cause or exacerbate hypertension
May cause serotonin syndrome when used with MAO inhibitors, antidepressants, or opioid drugs
May cause falling asleep during activities of daily living
May cause or exacerbate dyskinesia; consider levodopa dose reduction
May cause hallucinations and psychotic behavior
May cause problems with impulse control/compulsive behaviors
May cause withdrawal-emergent hyperpyrexia and confusion
Pharmacology & Mechanism of Action
The precise mechanism by which Safinamide Mesylate exerts its effect in Parkinson’s disease is unknown. Safinamide Mesylate is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.